Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.40 |
| ▸ | MC3R | P41968 | 8/20 | 0.40 |
| ▸ | MC1R | Q01726 | 3/20 | 0.40 |
| ▸ | MC5R | P33032 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732467 | 1.00 | MC4R (0.40) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL732466 | 1.00 | MC4R (0.40) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL733730 | 0.92 | MC4R (0.46) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL733729 | 0.92 | MC4R (0.46) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL731540 | 0.90 | MC4R (0.49) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL731541 | 0.90 | MC4R (0.49) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL731974 | 0.89 | MC4R (0.49) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL731973 | 0.89 | MC4R (0.49) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL732550 | 0.87 | MC4R (0.46) | MC4RMC3RMC1RMC5RKCNH2 | |
| SCHEMBL733437 | 0.87 | MC4R (0.41) | MC4RMC3RMC5RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC1R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.